Thank you for your interest in Cyprotex, the world’s largest contract research organization (CRO) specializing in ADME Tox and bioscience services.
Cyprotex was founded in 1999 by Dr. David Leahy. Dr. Leahy had two visions for the company. One of these visions was a reach for the stars:
To predict the ADME properties of any drug candidate molecule without having to put that molecule into a human or animal.
When Dr. Leahy had this vision, 40% of all drugs were failing in human clinical trials because of ADME failures. As human clinical trials are the most expensive step in bringing a new drug to market, this made ADME the single largest cause of inefficiency in drug development. Dr. Leahy’s dream was to totally eliminate this waste.
We are still far from reaching Dr. Leahy’s goal, but we have made great progress. Now only 7% of drugs fail in clinical trials due to ADME reasons. Sadly, the percentage of drugs failing in clinical trials remains at 80%, as other reasons for failure have grown.
Among these reasons for failure is toxicity. Not only is toxicity the largest reason for clinical trial failures, accounting for 43% of all Phase I failures, but unlike other reasons for failure, the cost of drug toxicity problems extends far beyond the cost of the failed clinical trials. Drugs that cause injury or death for some patients are being approved because clinical trials can’t detect the subtle toxicity problems that are becoming ever more common with new drugs. Such drugs have to be either removed from the market, or given ‘black box’ warnings greatly limiting whom they may be prescribed to. The costs incurred by toxicity include litigation and injury claims, and lost investment in commercialization. In total, these expenses make toxicity the most costly problem in drug discovery and development today.
The science needed to address the toxicity problem is similar to, albeit more complex than the science used to address the ADME problem. Hence, the ADME field has grown to include toxicity and is now referred to as ‘ADME Tox’ or ‘ADMET’.
Dr. Leahy’s other vision was that Cyprotex would become the world’s largest contract research organization specializing in ADMET. In August 2010 this dream began to be realized when Cyprotex acquired Apredica, a US-based ADME Tox provider with the industry’s most extensive portfolio of in vitro toxicology assays, including advanced, proprietary High Content Toxicology technology that Apredica had acquired from Cellumen to augment its existing High Content Toxicology service. More recently, Cyprotex replicated its highly successful high throughput ADME laboratory at this site in 2015, allowing US clients to more easily access these services from a local laboratory, and enabling us to streamline our key assays between the sites.
To supplement our growing presence in in vitro toxicology we bought the assets of CeeTox Inc. in January 2014. This purchase has afforded a new, additional, North American site (in Kalamazoo, MI) and also many new, proprietary toxicity screening assays. Many of these assays are employed by customers based in cosmetic, personal care and industrial chemical business sectors which are becoming increasingly important to Cyprotex as we seek to increase and diversify our client base. The purchase of CeeTox has also enabled us to offer novel Endocrine Disruption Screening Panels (EDSP) which US and European Government agencies are increasingly advocating to derisk the toxicity of ‘household’ chemicals through adverse endocrine effects.
Cyprotex expanded further in 2015 by introducing a new Bioscience division, adding phenotypic and target-based drug discovery screening to our portfolio of services and thus diversifying our offering and expanding our customer base.
Combining Cyprotex’s strengths in ADME, in vitro toxicology, Biosciences and in silico modeling allows Cyprotex to enjoy the following distinctions:
- The most extensive portfolio of ADME contract research services available anywhere, ranging from early discovery screening to late stage regulatory studies.
- The most highly automated platform for discovery ADME screening on the market, allowing our customers to enjoy unparalleled turnaround times, data quality, and cost efficiency for routine ADME screening – now available from our sites in the UK and US.
- Capabilities to customize existing assays as well as adapt and develop new ones to meet our customers’ unique needs.
- A high level of expertise in several specialist techniques including high content imaging, 3D cell-based models, microelectrode array, cellular bioenergetics and PBPK modeling.
- Cyprotex are the sole provider of CellCiphr® High Content Toxicology and SenCeeTox® skin sensitization services.
- We are the only company in the world with in-house expertise in both in silico and in vitro services.
- Over 1000 companies have entrusted their ADME Tox and Bioscience research to us. None of our direct competitors report a client base this large.
Our growth strategy includes a combined approach of internal expansion and M&A activity. In 2014 and 2015, we expanded our internal drug transporter, bioanalytical and toxicology capabilities at our UK site, introduced a new high throughput screening facility at our Watertown site, and launched our new Biosciences division. The Company continues to monitor and evaluate future opportunities for M&A in order to expand and diversify our offerings and customer base.
I have faith that Cyprotex will not only be as successful in addressing toxicity and efficacy as it has been in addressing ADME, I also believe that we will eventually reach our ultimate objective:
The ability to accurately predict the efficacy and ADME Tox properties of any potential drug or chemical prior to administering to a human or animal.
If you are a prospective customer, I encourage you to contact us to learn more about how Cyprotex can help you. Many of our customers are pharmaceutical or biotech companies. We help these companies progress compounds from discovery to IND (Investigational New Drug status) faster and with greater assurance, or work with them in development to generate high quality data for making decisions on clinical DDI studies. Our other customers are involved with chemicals such as cosmetics and agrochemicals. We help these companies determine the safety profiles of their compounds in the most rapid and cost-efficient manner.
If you are a prospective investor, Cyprotex has been traded on the London AIM since 2002, ticker symbol ‘CRX’. I encourage you to review our investor information in more detail, and consider adding Cyprotex to your portfolio.
If you are a prospective employee, Cyprotex offer an outstanding working environment for ADME Tox and Bioscience scientists. Because of our automated screening platform, much of the monotonous lab work scientists associate with jobs in contract research doesn’t exist here. Instead, our scientists focus on consulting with our clients on their ADME Tox and Bioscience issues, designing and performing customized experiments, and developing new assays. Further, because of our size and the large number of clients we work with, employment at Cyprotex is more stable than in the ramp-up then downsize cycles that are common in pharmaceutical companies these days. Please see our current job openings.
It is exciting to be here at Cyprotex, as we are privileged to be addressing some of today’s most important problems in drug discovery and consumer chemicals. I am honoured to have had this opportunity to tell you about what Cyprotex have achieved and look forward to achieving.Anthony D. Baxter, Ph.D.
Chief Executive Officer